Shares of Health Care sector company Moderna moved -0.8% today, and are now trading at a price of $79.95. The large-cap stock's daily volume was 3,335,217 compared to its average volume of 4,105,133. The S&P 500 index returned a 1.0% performance.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company is based in Cambridge and has 3,900 full time employees. Its market capitalization is $30,483,654,656.
19 analysts are following Moderna and have set target prices ranging from $52.0 to $300.0 per share. On average, they have given the company a rating of hold. At today's prices, MRNA is trading -40.41% away from its average analyst target price of $134.16 per share.
Over the last year, MRNA shares have gone down by -57.0%, which represents a difference of -74.0% when compared to the S&P 500. The stock's 52 week high is $217.25 per share and its 52 week low is $62.55. Although Moderna's average free cash flow over the last 6 years has been $2.72 Billion, they have been decreasing at an average rate of -35.1%. For this reason, investors may continue to shun the stock.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | -2,078,000 | 579,000 | -2,657,000 | -158.0 |
| 2022 | 4,981,000 | 400,000 | 4,581,000 | -65.65 |
| 2021 | 13,620,000 | 284,000 | 13,336,000 | 580.76 |
| 2020 | 2,027,000 | 68,000 | 1,959,000 | 498.98 |
| 2019 | -459,000 | 32,000 | -491,000 | -12.45 |
| 2018 | -330,865 | 105,766 | -436,631 |
